Upload
jasmine-carroll
View
216
Download
1
Tags:
Embed Size (px)
Citation preview
Alison Drake
International AIDS Society Conference
July 18, 2011
Valacyclovir suppression reduces breast milk and plasma HIV-1 RNA postpartum:
results of a randomized clinical trial
Abstracts at IAS 2011
Oral Abstract Session
Maternal Health and Paediatric OutcomesTUAB0202: Tuesday 2:30 – 4:00, MR 4
Poster ExhibitionsMOPE174: Monday 12:30 – 2:30TUPE268: Tuesday 12:30 – 2:30
MTCT in non-breastfeeding populations
Pregnancy Delivery Postpartum
ZDV sdNVP Maternal ZDV + 3TC (1 wk)Maternal HAART
Postnatal Tx rate
(6 mo)
1 - 2%1 - 2%Maternal HAART
MTCT in breastfeeding populations
Pregnancy Delivery Postpartum
ZDV sdNVP Maternal ZDV + 3TC (1 wk)Maternal HAART or Infant NVP
Postnatal Tx rate
(6 mo)
8 - 10%3 - 5%Maternal HAART
Cessation of BF
MTCT in breastfeeding populations
Access to ARVs for PMTCT not universal53% coverage in low- and middle- income countries (WHO 2010)
Alternative strategies needed to reduce postnatal transmission
Pregnancy Delivery Postpartum
ZDV sdNVP Maternal ZDV + 3TC (1 wk)Maternal HAART or Infant NVP
Postnatal Tx rate
(6 mo)
8 - 10%3 - 5%Maternal HAART
Cessation of BF
HSV-2 infection in HIV-1 infected women
Prevalence 75% to > 95%
Suppressive therapyReduces plasma HIV-1 RNA 0.25 - 0.5 log0.18 log greater reduction with valacyclovir (Ludema 2011)
Effect on breast milk HIV-1 RNA or MTCT unknown
AimsTo evaluate the effect of valacyclovir suppressive
therapy administered during late pregnancy and for 12 months postpartum on:
Plasma HIV-1 RNA levels
Breast milk HIV-1 RNA detection and levels
Study designInclusion criteriaProceduresHIV-1/HSV-2 seropositive≥ 18 years of ageHAART ineligible
CD4 > 250 cells/mm3
Seeking ANC in Nairobi, KenyaDeliver and remain in Nairobi
12 months postpartum
Double blind RCT 500 mg valacyclovir
or placebo bidPMTCT ARVs
ZDV + sdNVP
28-32wk 34wk 38wk 2wk 6wk 14wk 6mo 12mo
Study design
Pregnancy
Delivery
Postpartum
ScreenEnroll &
Randomize
Inclusion criteriaProceduresHIV-1/HSV-2 seropositive≥ 18 years of ageHAART ineligible
CD4 > 250 cells/mm3
Seeking ANC in Nairobi, KenyaDeliver and remain in Nairobi
12 months postpartum
Blood & breast milk
Double blind RCT 500 mg valacyclovir
or placebo bidPMTCT ARVs
ZDV + sdNVP
74 valacyclovir
74 placebo
73 included
in analysis
73 included
in analysis1 LTFU 1 LTFU
April 2008 – June 2009
359 screened
211 eligible
148 enrolled
Screening, enrollment, and follow-up
* not mutually exclusive
Ineligible *85 HSV-267 CD4
70 HAART24 Residence
Baseline and infant characteristicsMedian (IQR) or Mean* (95% CI) or n (%)
Characteristic Valacyclovir (n=73) Placebo (n=73)
Age (years) 25 (22 - 30) 25 (22 - 29)
Reported history of GUD 10 (14) 13 (18)
CD4 count (cells/mm3) 452 (351 - 560) 481 (340 - 598)
WHO stage 1 68 (93) 62 (85)
Plasma HIV-1 RNA (log10 copies/mL)* 3.89 (3.66 - 4.11) 3.87 (3.67 - 4.06)
Initiated ZDV by enrollment 73 (100) 68 (93)
Infant received sdNVP 67/72 (93) 70/71 (96)
Breastfeeding (reported at 2 weeks) 67/72 (93) 66/66 (100)
23
45
67
log
10
co
pie
s/m
L
0 4 8 12
Months postpartum
Postpartum plasma HIV-1 RNA levels
PlaceboValacyclovir
23
45
67
log
10
co
pie
s/m
L
0 4 8 12
Months postpartum
Postpartum plasma HIV-1 RNA levels
PlaceboValacyclovir
23
45
67
log
10
co
pie
s/m
L
0 4 8 12
Months postpartum
Postpartum plasma HIV-1 RNA levels
PlaceboValacyclovir
23
45
67
log
10
co
pie
s/m
L
0 4 8 12
Months postpartum
Postpartum plasma HIV-1 RNA levels
PlaceboValacyclovirp
2wk PVL 2- 6 wk rate of ∆ 3.10 2.08 2.83 1.48 0.11 <0.001
0.60 lower (95% CI 0.92 – 0.28)
23
45
67
log
10
co
pie
s/m
L
0 4 8 12
Months postpartum
Postpartum plasma HIV-1 RNA levels
PlaceboValacyclovirp
6 wk – 12 mo rate of ∆ Mean (95% CI) difference0.030.02 0.51 lower (0.73 – 0.30)0.3 <0.001
HIV-1 RNA detection in breast milk
RR 0.81 RR 0.70* RR 0.54* RR 0.84 RR 0.900
.2.4
.6.8
% w
ith H
IV-R
NA
de
tect
ed
2 week 6 week 14 week 6 month 12 monthPostpartum visit
Placebo Valacyclovir* p<0.05
23
45
6
log
10
co
pie
s/m
L
0 4 8 12
Months postpartum
Breast milk HIV-1 RNA levels
PlaceboValacyclovir
Breast milk Plasma Median (IQR)
6 wk 14 wk2.42 (1.70 – 3.35) 1.70 (1.70 – 2.96)1.70 (1.70 – 2.57) 1.70 (1.70 – 1.70)
23
45
6
log
10
co
pie
s/m
L
0 4 8 12
Months postpartum
Breast milk and plasma HIV-1 RNA levels
PlaceboValacyclovir
Median (IQR) 6 wk 14 wk2.42 (1.70 – 3.35) 1.70 (1.70 – 2.96)1.70 (1.70 – 2.57) 1.70 (1.70 – 1.70)
Breast milk Plasma
HR = 1.45(95% CI: 0.41 - 5.12)
0.00
0.10
0.20
Pro
bab
ility
of H
IV-1
tran
smis
sion
72 67(3) 66(0) 64(0) 64(0) 61(1) 41(2)Valacyclovir71 67(1) 64(2) 61(1) 60(0) 59(0) 43(0)Placebo
Number at risk
0 60 120 180 240 300 360
Age (days)
Risk of infant HIV-1 transmission
n = 6
n = 4
Conclusions
Valacyclovir reduced Early breast milk HIV-1 RNA detectionPlasma HIV-1 RNA 0.51 log
Plasma results consistent with other trials
Impact of valacyclovir on MTCT may differ from heterosexual transmission Prolonged exposure to bodily fluids 0.4 log lower viral load associated with reduced risk of
postnatal MTCT (Neveu 2011)
Implications
Valacyclovir is an appealing intervention
Valacyclovir suppressive therapy, in conjunction with PMTCT ARVs, should be evaluated as an intervention to reduce postnatal MTCT and improve maternal health
Acknowledgments
University of Washington Carey Farquhar Alison Roxby Anna Wald Grace John-Stewart Barbra Richardson Julie Overbaugh Jane Hitti Sandy Emery
University of Nairobi James Kiarie Francisca Ongecha-Owuor
Funding
NIH R03 5R03HD057773-02
NIH ARRA 5R03HD057773-02S1
University of Washington CFAR
P30 AI027757
CFAR STD Pre-doctoral Training Grant 5T32AI007140-33
Puget Sound Partners for Global Health
UW Royalty Research Fund
Study participants
Mathare staff
DSMB
GlaxoSmithKline